Sen. Thom Tillis (R-NC) (AP Photo/Alex Brandon)
January 17, 2024 12:31 PM EST
Pharma
FDA+

FDA+ roundup: Sen. Tillis goes af­ter Biden ad­min­is­tra­tion for sup­port­ing march-in rights

Lia DeGroot

Sen. Thom Tillis (R-NC) is push­ing back on the Biden ad­min­is­tra­tion’s plans for how it hy­po­thet­i­cal­ly would use its con­tro­ver­sial march …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times